Tag Archives: FDA clinical trials

Diabetes research has advanced rapidly over the past two decades, leading to groundbreaking medications such as GLP-1 receptor agonists, SGLT2 inhibitors, and dual incretin therapies. However, one challenge remains constant: developing new treatments through traditional clinical trials is often expensive, time-consuming, and inflexible. Could there be a better way to …

Read More »